Satoru Takahashi*, Ryosuke Tanaka, Satomi Okano, Akie Okayama, Nao Suzuki and Hiroshi Azuma
Department of Pediatrics, Asahikawa Medical University, Japan
Received date April 29, 2016; Accepted date May 23, 2016; Published date May 25, 2016
Citation: Takahashi S, Tanaka R, Okano S, Okayama A, Suzuki N, et al. (2016) Reduced Efficacy of Enzyme Replacement Therapy in a Child with Late-Onset Pompe Disease. Pediatr Ther 6:290. doi:10.4172/2161-0665.1000290
Copyright: ©2016 Takahashi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Pediatrics & Therapeutics
Pompe disease is an autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA), resulting in failure of lysosomal glycogen degradation. Patients with late-onset Pompe disease experience progressive muscle weakness and decreased respiratory function. Enzyme replacement therapy (ERT) for lateonset Pompe disease became available for clinical use in 2006. Clinical studies have since demonstrated beneficial effects on motor and respiratory functions in treatment periods up to 4 years. We report an 8-year period wherein a patient with late-onset Pompe disease received ERT with recombinant human GAA. The patient initially showed marked improvement in motor functions. However, these improvements stopped approximately 5 years after ERT, followed by progressive declines in muscle strength. Our case demonstrates that resistance to ERT might develop after long-term treatment. Elucidating the underlying mechanism is expected to have significant implications for the development of new therapeutic strategies in patients with late-onset Pompe disease.
Pompe disease, an autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA), results in failure of lysosomal glycogen degradation, leading to a progressive glycogen accumulation in tissues. Patients with late-onset Pompe disease experience progressive muscle weakness and decreased respiratory function. Enzyme replacement therapy (ERT) for Pompe disease supplements deficient GAA by intravenous administration of recombinant human GAA (rhGAA). ERT treatment is effective in stabilizing motor and respiratory functions in late-onset Pompe disease . The treatment for Pompe disease became available for clinical use in 2006; thus, long-term effects can be reported only now. We report an 8-year period wherein a patient with late-onset Pompe disease received ERT.
The patient, male and aged 16 years at the time of this report, was the first child of healthy unrelated Japanese parents. The patient was born at term after an uneventful pregnancy and was healthy in the neonatal period. Early motor development was not delayed: he could walk unaided at the age of 1 year and 3 months. At the age of 3 years, he suffered from influenza and was found to show elevated creatine kinase (CK) levels (1500–3000 U/l). An examination revealed mild muscle weakness with proximal dominance. Echocardiography was normal. Biopsied skeletal muscle showed many vacuoles filled with glycogen and with increased acid phosphatase activity. An enzyme assay revealed reduced GAA activity in the skin fibroblasts (0.76 nmol/mg protein per 30 min or 10.4% of the average control activity of 7.3 ± 2.2 nmol/mg protein per 30 min). Genetic analysis revealed compound heterozygous mutations of GAA : a newly discovered splicesite c.546G>T mutation and a recurrent missense p.R600C mutation .
Figure 1: (A) Effects of treatment on motor functions. Timed function tests were used as measures of motor functions before enzyme replacement therapy (ERT) and until 8 years of ERT. Times required for rising from supine position; (B) 10-meter walking; (C) and 10-step climbing, gradually decreased through 5 years after ERT, but thereafter increased again.
The patient started ERT at 7 years of age when he exhibited proximal dominant muscle weakness and difficulty in jumping and running. The patient received intravenous infusions (20 mg/kg body weight) of rhGAA every 2 weeks. After starting ERT, the patient exhibited a good clinical response with partial recovery of exercise abilities (Figure 1). He gained the ability to jump and could enjoy mountain climbing and skiing. Serum CK levels decreased by 42% of the levels before ERT (Figure 2). However, these improvements stopped approximately 5 years after ERT, and were followed by progressive declines in motor functions (Figure 1). Muscle weakness was more pronounced in the proximal muscles than the distal muscles and more in the lower extremities than the upper extremities. He showed Gower’s sign and a waddling gait. He could not jump and needed to hold a rail to climb stairs. Serum CK levels increased with clinical deteriorations (Figure 2). Whereas, pulmonary function remained stable. His percentage of predicted forced vital capacity (FVC) was 65.1% at 8 years of age and 69.1% at 15 years of age. Anti– rhGAA IgG antibodies became detectable by 2 years after ERT and remained at low titers, in the range of 1:200 and 1:800. No consistent association was found between serum IgG antibody titer and therapeutic efficacy. Serial computed tomography (CT) scans of the thigh muscles demonstrated no atrophic changes (Figure 3).
Clinical studies of ERT for late-onset Pompe disease demonstrate beneficial effects on motor and respiratory functions in treatment periods up to 4 years [1,3]. We report here an 8-year period wherein a patient with late-onset Pompe disease received ERT. The patient initially improved in terms of motor functions, but began to deteriorate after 4-5 years on ERT. Timed function tests clearly demonstrated changes in his muscle strength over time. Serum CK levels were a useful indicator of the treatment response: its reduction and elevation corresponded well with clinical improvement and deterioration, respectively.
In ERT, intravenously administrated rhGAA is endocytosed at the plasma membrane and delivered to lysosomes. ERT efficacy depends on the accessibility of the affected cells to the infused enzyme. Uptake of the rhGAA is mediated by the cation-independent mannose-6- phosphate receptors (CI-MPRs). Expression levels of CI-MPR vary between tissues with the highest expression noted in the liver and heart and the lowest expression noted in skeletal muscles . A predominant feature of late-onset Pompe disease is the early development of respiratory failure because of diaphragmatic involvement. A study demonstrated progressive deterioration of pulmonary function, showing mean annual declines of 1.6% in the percentage of predicted FVC . Considering the progressive nature of this disease, stabilization of pulmonary function in this patient could be considered a positive treatment outcome. CI-MPR expression in the diaphragm is higher than in skeletal muscles . Therefore, the poor response of skeletal muscles might be attributed, at least in part, to the low abundance of CI-MPR. New therapeutic approaches such as drugs enhancing CI-MPR expression or chemically modified rhGAA with high receptor affinity may contribute to overcome poor enzyme uptake by skeletal muscles.
Earlier model animal studies of Pompe disease demonstrated that incomplete lysosomal glycogen degradation disrupted autophagy, a major lysosome-dependent degradation pathway, resulting in intracellular accumulation of autophagic vacuoles . Autophagic build-up causes muscle fiber damages and interferes with delivery of infused enzymes to lysosomes . Elucidating the mechanism underlying the age-dependent development of ERT resistance is expected to have significant implications for the development of new therapeutic strategies in patients with late-onset Pompe disease.
We thank the patient and his parents for their willingness to participate in this report. We also thank Dr. Hideo Sugie for his assistance with the enzyme assay and Drs. Ichizo Nishino and Ikuya Nonaka for their assistance in pathological diagnosis.